The estimated Net Worth of Sachs Group Incgoldman Sach... is at least $239 millió dollars as of 8 November 2023. Sachs Sach owns over 72,874 units of Panbela Therapeutics stock worth over $139,284 and over the last 21 years Sachs sold PBLA stock worth over $239,049,217.
Sachs has made over 48 trades of the Panbela Therapeutics stock since 2005, according to the Form 4 filled with the SEC. Most recently Sachs sold 72,874 units of PBLA stock worth $51,741 on 8 November 2023.
The largest trade Sachs's ever made was selling 5,243,185 units of Panbela Therapeutics stock on 17 May 2012 worth over $197,038,892. On average, Sachs trades about 98,247 units every 72 days since 2003. As of 8 November 2023 Sachs still owns at least 397,954 units of Panbela Therapeutics stock.
You can see the complete history of Sachs Sach stock trades at the bottom of the page.
Sachs's mailing address filed with the SEC is 200 WEST STREET200 WEST STREET, , NEW YORKNEW YORK, NYNY, 1028210282.
Over the last 4 years, insiders at Panbela Therapeutics have traded over $51,741 worth of Panbela Therapeutics stock and bought 406,888 units worth $0 . The most active insiders traders include Sachs Group Incgoldman Sach..., Donald Robert Schemel és Michael T. Cullen. On average, Panbela Therapeutics executives and independent directors trade stock every 67 days with the average trade being worth of $27,986. The most recent stock trade was executed by Sachs Group Incgoldman Sach... on 8 November 2023, trading 72,874 units of PBLA stock currently worth $51,741.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Panbela Therapeutics executives and other stock owners filed with the SEC include: